Literature DB >> 15466376

Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion.

Anil K Sood1, Jeremy E Coffin, Galen B Schneider, Mavis S Fletcher, Barry R DeYoung, Lynn M Gruman, David M Gershenson, Michael D Schaller, Mary J C Hendrix.   

Abstract

Focal adhesion kinase (FAK) is a nonreceptor tyrosine kinase that is activated by integrin clustering. There are limited data regarding the functional role of FAK in ovarian cancer migration and invasion. In the current study, FAK expression was evaluated in ovarian cell lines (nontransformed and cancer), 12 benign ovarian samples, and in 79 invasive epithelial ovarian cancers. All three ovarian cancer cell lines overexpressed FAK compared to the nontransformed cells. The dominant-negative construct called FAK-related nonkinase (FRNK) was introduced into two ovarian cancer cell lines (SKOV3 and 222). FRNK promoted FAK dephosphorylation without changing total FAK levels in these cell lines. Furthermore, FRNK decreased the in vitro invasive ability of ovarian cancer cells by 56 to 85% and decreased migration by 52 to 68%. FRNK-transfected cells also displayed poor cell spreading. Immunohistochemical analysis revealed that the surface epithelium from all benign ovarian samples had weak FAK expression. In contrast, 68% of invasive ovarian cancers overexpressed FAK. FAK overexpression was significantly associated with high tumor stage, high tumor grade, positive lymph nodes and presence of distant metastasis (all P values <0.05). FAK overexpression was also associated with shorter overall survival (P = 0.008). Multivariate analysis revealed that FAK overexpression and residual disease >1 cm were independent predictors of poor survival. These data indicate that FAK is overexpressed in most invasive ovarian cancers and plays a functionally significant role in ovarian cancer migration and invasion. Thus, FAK may be an important therapeutic target in ovarian carcinoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15466376      PMCID: PMC1618649          DOI: 10.1016/S0002-9440(10)63370-6

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  52 in total

Review 1.  Signaling through focal adhesion kinase.

Authors:  D D Schlaepfer; C R Hauck; D J Sieg
Journal:  Prog Biophys Mol Biol       Date:  1999       Impact factor: 3.667

2.  Focal adhesion kinase: an integrin-linked protein tyrosine kinase.

Authors:  M D Schaller; J T Parsons
Journal:  Trends Cell Biol       Date:  1993-08       Impact factor: 20.808

3.  Focal adhesion assembly.

Authors:  K Burridge; M Chrzanowska-Wodnicka; C Zhong
Journal:  Trends Cell Biol       Date:  1997-09       Impact factor: 20.808

4.  Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer.

Authors:  L V Owens; L Xu; G A Dent; X Yang; G C Sturge; R J Craven; W G Cance
Journal:  Ann Surg Oncol       Date:  1996-01       Impact factor: 5.344

5.  Both focal adhesion kinase and c-Ras are required for the enhanced matrix metalloproteinase 9 secretion by fibronectin in ovarian cancer cells.

Authors:  K Shibata; F Kikkawa; A Nawa; A A Thant; K Naruse; S Mizutani; M Hamaguchi
Journal:  Cancer Res       Date:  1998-03-01       Impact factor: 12.701

6.  Expression of focal adhesion kinase gene and invasive cancer.

Authors:  T M Weiner; E T Liu; R J Craven; W G Cance
Journal:  Lancet       Date:  1993-10-23       Impact factor: 79.321

7.  Autonomous expression of a noncatalytic domain of the focal adhesion-associated protein tyrosine kinase pp125FAK.

Authors:  M D Schaller; C A Borgman; J T Parsons
Journal:  Mol Cell Biol       Date:  1993-02       Impact factor: 4.272

8.  v-Src-induced degradation of focal adhesion kinase during morphological transformation of chicken embryo fibroblasts.

Authors:  V J Fincham; J A Wyke; M C Frame
Journal:  Oncogene       Date:  1995-06-01       Impact factor: 9.867

9.  Focal adhesion kinase suppresses Rho activity to promote focal adhesion turnover.

Authors:  X D Ren; W B Kiosses; D J Sieg; C A Otey; D D Schlaepfer; M A Schwartz
Journal:  J Cell Sci       Date:  2000-10       Impact factor: 5.285

10.  Focal adhesion kinase mediates the integrin signaling requirement for growth factor activation of MAP kinase.

Authors:  M W Renshaw; L S Price; M A Schwartz
Journal:  J Cell Biol       Date:  1999-11-01       Impact factor: 10.539

View more
  110 in total

1.  Targeted gene silencing using RGD-labeled chitosan nanoparticles.

Authors:  Hee Dong Han; Lingegowda S Mangala; Jeong Won Lee; Mian M K Shahzad; Hye Sun Kim; Deyu Shen; Eun Ji Nam; Edna M Mora; Rebecca L Stone; Chunhua Lu; Sun Joo Lee; Ju Won Roh; Alpa M Nick; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Clin Cancer Res       Date:  2010-06-10       Impact factor: 12.531

2.  Subcutaneous passage increases cell aggressiveness in a xenograft model of diffuse large B cell lymphoma.

Authors:  Rosa Bosch; María José Moreno; Rebeca Dieguez-Gonzalez; María Virtudes Céspedes; Alberto Gallardo; Josep Nomdedeu; Miguel Angel Pavón; Iñigo Espinosa; Maria Antònia Mangues; Jorge Sierra; Isolda Casanova; Ramon Mangues
Journal:  Clin Exp Metastasis       Date:  2012-01-20       Impact factor: 5.150

3.  PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer.

Authors:  Duangmani Thanapprapasr; Rebecca A Previs; Wei Hu; Cristina Ivan; Guillermo N Armaiz-Pena; Piotr L Dorniak; Jean M Hansen; Rajesha Rupaimoole; Jie Huang; Heather J Dalton; Rouba Ali-Fehmi; Robert L Coleman; Anil K Sood
Journal:  Mol Cancer Ther       Date:  2015-04-01       Impact factor: 6.261

Review 4.  Mechanogenomic control of DNA exposure and sequestration.

Authors:  Gary S Stein
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

Review 5.  Biobehavioral influences on cancer progression.

Authors:  Erin S Costanzo; Anil K Sood; Susan K Lutgendorf
Journal:  Immunol Allergy Clin North Am       Date:  2011-02       Impact factor: 3.479

6.  Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells.

Authors:  Jyotsnabaran Halder; Charles N Landen; Susan K Lutgendorf; Yang Li; Nicholas B Jennings; Dominic Fan; Gina M Nelkin; Rosemarie Schmandt; Michael D Schaller; Anil K Sood
Journal:  Clin Cancer Res       Date:  2005-12-15       Impact factor: 12.531

Review 7.  Multifunctional nanoparticles for cancer immunotherapy.

Authors:  Tayebeh Saleh; Seyed Abbas Shojaosadati
Journal:  Hum Vaccin Immunother       Date:  2016-02-22       Impact factor: 3.452

8.  Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.

Authors:  Rebecca L Stone; Keith A Baggerly; Guillermo N Armaiz-Pena; Yu Kang; Angela M Sanguino; Duangmani Thanapprapasr; Heather J Dalton; Justin Bottsford-Miller; Behrouz Zand; Rehan Akbani; Lixia Diao; Alpa M Nick; Koen DeGeest; Gabriel Lopez-Berestein; Robert L Coleman; Susan Lutgendorf; Anil K Sood
Journal:  Cancer Biol Ther       Date:  2014-04-23       Impact factor: 4.742

9.  Targeting signaling pathways of VEGFR1 and VEGFR2 as a potential target in the treatment of breast cancer.

Authors:  Maryam Farzaneh Behelgardi; Saber Zahri; Zahra Gholami Shahvir; Farhad Mashayekhi; Laleh Mirzanejad; S Mohsen Asghari
Journal:  Mol Biol Rep       Date:  2020-02-18       Impact factor: 2.316

10.  Expression and clinical significance of focal adhesion kinase in the two distinct histological types, intestinal and diffuse, of human gastric adenocarcinoma.

Authors:  Constantinos T Giaginis; Stephanie Vgenopoulou; Gerasimos S Tsourouflis; Ekaterini N Politi; Gregorios P Kouraklis; Stamatios E Theocharis
Journal:  Pathol Oncol Res       Date:  2008-11-06       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.